Abstract 2398: Activity of the PARP inhibitor olaparib in ATM-deficient gastric cancer: from preclinical models to the clinic

Darren Hodgson(AstraZeneca (United Kingdom)), Mark J. O’Connor(AstraZeneca (United Kingdom)), Lenka Oplustilova(AstraZeneca (United Kingdom)), Chris Harbron(Roche (United Kingdom)), J. Carl Barrett(National Institute of Environmental Health Sciences), Andrew Dickinson(Plymouth Hospital), Yung‐Jue Bang(Seoul National University), Alan Lau(AstraZeneca (United Kingdom)), Anitra Fielding(AstraZeneca (United States)), Seock‐Ah Im(Seoul National University), Brian Dougherty(AstraZeneca (United States)), Chris Womack, James Bradford(AstraZeneca (United Kingdom)), Lai Zhongwu(AstraZeneca (United Kingdom)), Helen Mason(St George's, University of London), Jane Robertson(Cancer Research UK), Matthew McLoughlin(Wellcome/MRC Cambridge Stem Cell Institute), Xiaolu Yin(AstraZeneca (Singapore)), Yi Gu, Helen Jones(AstraZeneca (United Kingdom)), Woo Ho Kim(Seoul National University)
Cancer Research
October 1, 2014
10.1158/1538-7445.am2014-2398
Cited by 7

Related Papers

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
|The Lancet|2010|7.3k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
The complete genome sequence of the gastric pathogen Helicobacter pylori
|Nature|1997|3.6k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k